Tumor vaccines may make the body build an immune response to kill tumor cells. This research study is evaluating a new type of tumor vaccine termed as "Neoantigen Tumor Vaccine". The purpose of this phase I/II trial study is to assess the safety and effectiveness of neoantigentumor vaccine in post radical operation patients with stage IIIA lung cancer.

开始日期2024-01-16

申办/合作机构

湖南省肿瘤医院

[+1]

100 项与 NeoAntigen Tumor Vaccine(Shanghai Houchao Biotechnology) 相关的临床结果

登录后查看更多信息

100 项与 NeoAntigen Tumor Vaccine(Shanghai Houchao Biotechnology) 相关的转化医学

登录后查看更多信息

100 项与 NeoAntigen Tumor Vaccine(Shanghai Houchao Biotechnology) 相关的专利（医药）

登录后查看更多信息

项与 NeoAntigen Tumor Vaccine(Shanghai Houchao Biotechnology) 相关的文献（医药）

2022-08-01·Advanced Science

A Potent Micron Neoantigen Tumor Vaccine GP‐Neoantigen Induces Robust Antitumor Activity in Multiple Tumor Models

Article

作者: Jing, Zhe ; Tang, Qian ; Li, Wenjing ; Wang, Shuqing ; Liu, Yanting ; Su, Kailing ; Zheng, Wei ; Xu, Keyuan ; Shi, Haobo ; Hong, Zhangyong

AbstractTherapeutic tumor neoantigen vaccines have been widely studied given their good safety profile and ability to avoid central thymic tolerance. However, targeting antigen‐presenting cells (APCs) and inducing robust neoantigen‐specific cellular immunity remain challenges. Here, a safe and broad‐spectrum neoantigen vaccine delivery system is proposed (GP‐Neoantigen) based on β‐1,3‐glucan particles (GPs) derived from Saccharomyces cerevisiae and coupling peptide antigens with GPs through convenient click chemistry. The prepared system has a highly uniform particle size and high APC targeting specificity. In mice, the vaccine system induced a robust specific CD8+ T cell immune response and humoral immune response against various conjugated peptide antigens and showed strong tumor growth inhibitory activity in EG7·OVA lymphoma, B16F10 melanoma, 4T1 breast cancer, and CT26 colon cancer models. The combination of the toll‐like receptors (TLRs) agonist PolyI:C and CpG 2395 further enhanced the antitumor response of the particle system, achieving complete tumor clearance in multiple mouse models and inducing long‐term rejection of reinoculated tumors. These results provide the broad possibility for its further clinical promotion and personalized vaccine treatment.

100 项与 NeoAntigen Tumor Vaccine(Shanghai Houchao Biotechnology) 相关的药物交易

登录后查看更多信息